Tumor mutation burden: from comprehensive mutational screening to the clinic
| العنوان: | Tumor mutation burden: from comprehensive mutational screening to the clinic |
|---|---|
| المؤلفون: | Jutta Deckert, Fotios Loupakis, Francesca Galuppini, Carlo Alberto Dal Pozzo, Raffaele Baffa, Matteo Fassan |
| المصدر: | Cancer Cell International Cancer Cell International, Vol 19, Iss 1, Pp 1-10 (2019) |
| بيانات النشر: | BioMed Central, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Immunotherapy, Next generation sequencing, Target therapy, Tumor mutation burden, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Immune checkpoint inhibitors, Context (language use), medicine.disease_cause, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Genetics, medicine, lcsh:QH573-671, Predictive biomarker, Mutation, lcsh:Cytology, business.industry, Molecular pathology, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Biomarker (cell), Clinical trial, 030220 oncology & carcinogenesis, Minireview, business |
| الوصف: | The recent advent of immunomodulatory therapies into the clinic has demanded the identification of innovative predictive biomarkers to identify patients most likely to respond to immunotherapy and support the design of tailored clinical trials. Current molecular testing for selection of patients with gastrointestinal or pulmonary carcinomas relies on the prevalence of PD-L1 expression in tumor as well as immune cells by immunohistochemistry and/or on the evaluation of the microsatellite status. Tumor Mutational Burden (TMB) has emerged as a promising novel biomarker in this setting to further aid in patient selection. This has been facilitated by the increasing implementation of molecular pathology laboratories with comprehensive next generation sequencing (NGS) technologies. However, the significant overall costs and expertise required for the interpretation of NGS data has limited TMB evaluation in routine diagnostics, so far. This review focuses on the current use of TMB analysis in the clinical setting in the context of immune checkpoint inhibitor therapies. |
| اللغة: | English |
| تدمد: | 1475-2867 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6e3199474288539f5466ea980ff1eb5Test http://europepmc.org/articles/PMC6686509Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....f6e3199474288539f5466ea980ff1eb5 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14752867 |
|---|